B cell lymphoma immunotherapy using TLR9-targeted oligonucleotide STAT3 inhibitors
Growing evidence links the aggressiveness of non-Hodgkin’s lymphoma, especially the activated B cell-like type diffuse large B cell lymphomas (ABC-DLBCLs) to Toll-like receptor 9 (TLR9)/MyD88 and STAT3 transcription factor signaling. Here, we describe a dual-function molecule consisting of a clinically relevant TLR9 agonist (CpG7909) and a STAT3 inhibitor in the form of a high-affinity decoy […]
Alan Horsager, Ph.D.
President, CEO, & Director
Marcin Kortylewski, Ph.D.
Senior Scientific Advisor, Professor, & Co-founder of Olimmune
John Rossi, Ph.D.
Professor and Co-Founder of MiNA & Dicerna
Nagy Habib, M.D.
Professor & Co-Founder of MINA Therapeutics
Scopus Presentation on Launch of Duet Therapeutics, its Wholly-Owned Subsidiary Focused on Immuno-Oncology
